Member Info for Billy-Bunter

I'm, sure the CTA announcement will come. To be precise, "mid-2022" to use Sareum's own words is the very end of June, very start of July. I take that to mean we are looking at plus or minus that by some amount. So, nobody should be falling off there chairs if this happens in July. Anyone invested just needs to tolerate lower trade volumes and some share price drift in the meantime.

I do agree with Lazarus, that there should be more news releases during H2 of this year, than there has been in H1. And, I think that the next year will be the making, or not, of Sareum.

Bill.

No need to apologise, WiP

I’ll just say I think quite a few have been misreading my intentions here.

Have a good night.

Bill

* I didn’t see your post you referred to.

Thanks, WiP

Regret, I’ve been doing my best doing a deeper dive on Sareum. At times I’ve not been able to read every post. I did see the one you referred to. As you’ve raise it, I’ll go back and take a look.

As for the “ wouldn’t put it past them to sit on assets to deny competitors access”. No, I didn’t say that. If you look it’s was earlier post from Star786.

I was actually throwing my hands up in the air, saying and people are accusing me of being negative, what about that….

Thanks,

Bill

I never doubted the acquisition due diligence covering this. What I'd been looking for was some explicit SRA737 recognition by GSK.

As you say Heckler, its comforting.

Bill

I really, really hope you are right Celtic. And, the paragraph in that press release gives some definite comfort.

Bill

wouldn't put it past them to sit on the assets to deny competitors access

And people are accusing me of being negative....

Bill

Good evening, everyone.

Completely by accident, I just stumbled across this, on the GSK web site. Its good news:

https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-acquire-late-stage-biopharmaceutical-company-sierra-oncology-for-19bn/

I'd like to draw everyone's attention to the paragraph section that I'm copying directly below here

****Sierra Oncology is a late-stage biopharmaceutical company based in San Mateo, California, on a mission to deliver targeted therapies that treat rare forms of cancer. In addition to momelotinib, the pipeline consists of two assets in phase I SRA515 and SRA737. SRA515 is a selective bromodomain-containing protein 4 (BRD4) bromodomain and extra-terminal domain (BET) inhibitor with a novel bivalent binding mode that inhibits both protein bromodomains, and SRA737 is a novel checkpoint kinase 1 (CHK1) inhibitor.****

So, GSK have in fact acknowledged SRA737, the Sareum Chk1 inhibitor, in a press release of their own . I think we may all have missed this because we've been looking at RNS documents and this was put out by GSK as a basic press release.

So, GSK have acknowledged SRA737.....

I'm going to celebrate with a beer.

Bill

P.S. And, here is the definition of the Progress Report, which essentially sets out its required content. And then, the also referred to Clinical Development Plan which is central to the Progress Report and sets out timelines

[“Progress Report” means a summary written report produced by ProNAi in respect of: (i) the progress of development of Licensed Products in relation to the then-current Clinical Development Plan; (ii) if relevant, the progress of any applications for Registration and (where relevant) Price Approvals for Licensed Products, and (iii) the progress of and plans for marketing and sale of Licensed Products. ProNAi agrees that each Progress Report shall include information that is reasonably sufficient for CPF to be able to ascertain ProNAi’s progress with respect to the Key Activities, in order for CPF to fulfil its reporting obligations to CRT/ICR under the Upstream Licence Agreement. ProNAi shall provide Progress Reports at the frequency set forth in Clause 4.5.

[“Clinical Development Plan” means the plan which sets forth a detailed overview of the intended clinical development of each Licensed Product, including without limitation a summary of all material development activities to be conducted by or on behalf of ProNAi for the purposes of obtaining Regulatory Approval for Licensed Products in the Territory, together with associated timelines for such activities. An exemplary Clinical Development Plan has been prepared prior to the Effective Date and appended at Schedule 9. The Clinical Development Plan shall be updated at least annually by ProNAi and details of any material updates shall be set forth in the next applicable Progress Report and provided to CPF in accordance with Clause 4.4.1.]

Bill

Good afternoon, SOG

From my reading of this, I think which of the first two 4.5 sub clauses applies right now comes down to the IND definition used in the agreement.

[“IND” means an investigational new drug application filed with the FDA necessary to commence human clinical trials].

Has an application to the FDA for human trials been submitted by Sierra? I'm aware there's been a safety study, but it was done in the UK, outside of the FDA's direct sphere of influence. So, I think Sierra are currently prior to that milestone, as you say, looking at the studies designs in preparation for trials.

Thus if SAR are pre-IND FDA submission stage, then its sub clause 4.5.1 that is currently applicable, and it requires that a ‘Progress Report’ be given to the CPF each year during January/February and the July/August windows. And, sub-clauses 4.5.3 and 4.5.4 go on to deal with the back and forth of these communications between Sierra and CPF.

So, an update will need to be given to the CPF in the two months immediately following the GSK acquisition. This looks like good timing with GSK having come along. I'm sure the CPF will have lots of questions about where things go from here. I wonder what agreement Sareum has with the CPF regarding the sharing on of said updates?

Bill

Hey HBD. Good find. I saw there was a full copy of the merger agreement, which I scanned through with interest.

I wish we had a similar full view of the agreement between the CRT Pioneer Fund and Sierra. But, not so luckily

Regarding your closing comment, I did actually make a few notes on GSK when I was looking at them earlier in the past week. Drawing from my notes for anyone who is interested, based upon last years figures, GSK makes sales of £93 million per day. And, generate free-flowing cash (essentially the cash available to invest) of £12M a day. No too shabby.

Bill

Thanks, Thoth2. Can you share a link to the tweet?
And, I hope your health is improving.
Bill

One other thought that just popped into my head on the GSK/SAR737 topic.

Has anyone been looking at the GSK board on here? There hasn't been a single post there about the Sierra acquisition. Would it be worth one of us going on there and placing a short post, explaining that Sierra has SRA737, what its is and why it might be interesting to GSK. Would be interesting to see what the reaction and feedback is.

Bill

Thanks ndr50. We've got carers coming in and I try to use that time to take mu Mother out and away from this, to give her a break. She's my Father's primary carer and its taking a toll on her.
You used the word sentiment and I think that sums this up. GSK haven't put out a direct reference to SRA737 and so its for each of us to take a view based upon our individual sentiment as to whether or not GSK will pick up the SRA737 ball. No one should shoot any other person down here for their views because we are all guessing. There are factors we can point to that help refine taking a view, but in the end its still guesswork.

For myself I think I'm homing in on being 25% confident that GSK will run with SRA737, based upon the information I've got to hand. Bear in mind I'm a cautious person rather than an out and out optimist. 'IF' they proceed, we'll likely hear about it through a GSK quarterly report and accompanying GSK pipeline update rather than an individual GSK RNS. And, I expect this to take time as trials work will be the trigger. Or, via an announcement from Sareum that they've received a first payment for dosing of a trial participant.

If they don't go ahead, I suspect we'll hear that from Sareum also rather than GSK, as I think SRA737 isn't currently big enough to be material to the overall GSK business and thus stock market reporting rules. That is unless Potnak is right, and GSK license on SRA737 to another party - in that case I think they would comment on it in some way though a joint press release.

Just my opinion.

Bill.

Not a problem, Fearg
You are clearly very bullish on GSK. Some others on here think that GSK will pass on 737. I'm still trying to decide, though I'm definitely not in the "its a 100% given that GSK will go ahead with this" extreme end of things. That would have required a more explicit reference to SRA737 by GSK.
Safe travels
B.

And, I hope you are right, Fearg!
I just wish the research I flagged up this morning showed GSK using a similar method as SRA737 rather than antibodies for checkpoints. Its not to say they won't pick this up, as they clearly are interest in immuno-therapy and the use of checkpoints. Plus, GSK own Niraparib / Zejula which has already undergone some testing with SRA737 in 2018.

But, it would have given us all a very nice and neat thing to cling to if there had been a more direct link in GSK's own published documentation.

And, Thoth2, thanks for your reply to my post, to make clear the antibody thing. Have I missed anything else out here in your view regarding GSK?

Bill

Thanks, Celtic
Thought you were referring to a few of my own predictive text mistakes on here. Why I asked twice.
Hope you are enjoying the hot weather.
Bill

Good afternoon, ndr50

Yes, I had read the Edison Report, shortly after it was released. It came across as a well written piece.

Regarding my current posts and the questions I've been asking, the part in the Edison report regarding 737 was written before GSK came along. I'd really be interested in their view now that GSK are on the scene.

As they set out in the document, it was looking like Sierra might at last progress SRA737, having got towards the end of the development/regulatory process with Momo. And some cash in the bank to play with following a fund raise. That was the outlook when I initially bought back into Sareum at the £1,50s and I'd say it was a straight forward outlook, where there was a real chance we might actually hear something on a shorter rather than longer timescale.

As we now all know GSK is on the scene, a much bigger company carrying more gravitas, resources and cash. Maybe this will be good for 737, maybe it won't - all depends on where GSK want to go with their pipeline portfolio. I want to try and understand this, hence some of my questions, research and thoughts I've put out there.

Thanks,

Bill

Thank you, Celtic, I will try and slow down a bit. I'm just juggling a lot here at the moment with what I referred to in an earlier post below. Its very, very sad to see a loved on so degraded..... If I could just take this from my Father I would do it.

Anyway, are you please able to enlighten me regarding the "himter" thing?

And, do you please have any comments on my GSK question? You do seem well versed in this area and I appreciate some of the information you put forwards before a thread got taken down earlier this week.

Bill

Doh, got in a fix for a moment.... Posting my himter question hopefully for the last time.

Does anyone actually know what Celticx007's' use of the word "himter" actually mean/relates to? Maybe I'm not worldly enough to know. Can someone enlighten me...?

Lutonnews, sincere apologies for putting in your name to my post below by accident.

Bill